Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 31543152.
- Also identified by DOI 10.1016/j.kint.2019.05.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bardoxolone methyl activates nuclear factor erythroid 2-related factor 2 and increases glomerular filtration rate in patients with diabetic kidney disease. Because bardoxolone methyl also increases albuminuria, Rossing and colleagues performed a retrospective analysis of the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) study and attributed increased albuminuria to increased estimated glomerular filtration rate. Although the study emphasizes bardoxolone methyl's benefits in diabetic kidney disease, we must be careful about interpretation.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Renal Insufficiency, Chronic